[Cancers of the prostate and cyproterone acetate. Value of blood testosterone and PSA levels for treatment surveillance].
On the basis of a retrospective series of 74 patients with adenocarcinoma of the prostate, the authors study the survival of these patients according to the clinical stage of the lesion when treated with cyproterone acetate. Biologically speaking, the authors have studied the evolution of the blood testosterone level, as well as of PSA and PAPs. Their conclusion is that the PSA is an excellent indicator of the efficacy of the cyproterone acetate treatment. Its fast decrease proves treatment efficacy, while a new rise indicates the resumption of evolution of the neoplastic process and must lead to change the therapeutic approach.
Aubert
J
J
Service d'Urologie, CHU de Poitiers.
Dore
B
B
Irani
J
J
Bon
D
D
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood*; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D017373:Cyproterone Acetate; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies; D013739:Testosterone / Q000097:blood*
D000951:Antigens, Neoplasm; D013739:Testosterone; D017373:Cyproterone Acetate; D003534:Cyproterone; D017430:Prostate-Specific Antigen
Cancers prostatiques et acétate de cyprotérone. Intérêt de la testostéronémie et du PSA pour la surveillance du traitement.